Industry News
Biotechnology Industry News
Oncology biotech Atreca pulled into industry’s layoff whirlpool, cuts 25% of staff
Oncology biotech Atreca pulled into industry’s layoff whirlpool, cuts 25% of staff gmasson Thu, 06/02/2022 - 10:37
Enochian CEO, facing short-seller attack, tries to distance biotech from co-founder arrested in murder-for-hire-plot
Enochian CEO, facing short-seller attack, tries to distance biotech from co-founder arrested in murder-for-hire-plot aarmstrong Thu, 06/02/2022 - 09:42
PARADIGME shift: Nordic Nanovector reviews stuttering cancer trial as enrollment grinds to a halt
PARADIGME shift: Nordic Nanovector reviews stuttering cancer trial as enrollment grinds to a halt ntaylor Thu, 06/02/2022 - 07:24
Roche pays Repare $125M to join Big Pharma peers in cancer race
Roche pays Repare $125M to join Big Pharma peers in cancer race ntaylor Thu, 06/02/2022 - 04:35
Merck KGaA nabs another baton in protein degradation race with $554M Proxygen deal
Merck KGaA nabs another baton in protein degradation race with $554M Proxygen deal mbayer Wed, 06/01/2022 - 23:45
Oncology trial starts hit record levels as COVID disruptions ease: report
Oncology trial starts hit record levels as COVID disruptions ease: report aarmstrong Wed, 06/01/2022 - 20:58
Samantha Truex did a rare thing last time she was CEO: admit defeat. She’s back with a new biotech and $200M
Samantha Truex did a rare thing last time she was CEO: admit defeat. She's back with a new biotech and $200M aarmstrong Wed, 06/01/2022 - 16:57
From Big Pharma to little Tessera, Michael Severino rewrites his next chapter as CEO of Flagship biotech
From Big Pharma to little Tessera, Michael Severino rewrites his next chapter as CEO of Flagship biotech gmasson Wed, 06/01/2022 - 12:37
Amgen’s heart drug reduces cardiovascular disease risk factor in phase 2 trial
Amgen's heart drug reduces cardiovascular disease risk factor in phase 2 trial aarmstrong Wed, 06/01/2022 - 11:02
Tech-Enabled Trials Don’t Have to Mean Loss of Human Connection
Tech-Enabled Trials Don't Have to Mean Loss of Human Connection mwen Wed, 06/01/2022 - 11:00
BioMarin’s hemophilia A gene therapy further delayed amid new FDA questions
BioMarin's hemophilia A gene therapy further delayed amid new FDA questions mbayer Wed, 06/01/2022 - 10:06
Sanofi’s Hemlibra rival gets step closer to approval with FDA breakthrough tag
Sanofi’s Hemlibra rival gets step closer to approval with FDA breakthrough tag jwaldron Wed, 06/01/2022 - 09:55
SKYLARK sings: Sage, Biogen hatch positive phase 3 data in postpartum depression
SKYLARK sings: Sage, Biogen hatch positive phase 3 data in postpartum depression ntaylor Wed, 06/01/2022 - 07:39
GO! Astellas picks up partner in convertibleCAR for backloaded $780M antibody project
GO! Astellas picks up partner in convertibleCAR for backloaded $780M antibody project ntaylor Wed, 06/01/2022 - 06:43
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final test
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final test jwaldron Wed, 06/01/2022 - 05:19
After Axsome’s migraine med rejection, phase 3 data keeps hope alive for depression drug
After Axsome’s migraine med rejection, phase 3 data keeps hope alive for depression drug gmasson Tue, 05/31/2022 - 10:44
After Axsome’s migraine med rejection, phase 3 data keep hope alive for depression drug
After Axsome's migraine med rejection, phase 3 data keep hope alive for depression drug gmasson Tue, 05/31/2022 - 10:44
After oncology wind-down, TG’s pivot to MS faces setback as FDA pushes approval decision
After oncology wind-down, TG's pivot to MS faces setback as FDA pushes approval decision jwaldron Tue, 05/31/2022 - 08:53
Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to market
Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to market ntaylor Tue, 05/31/2022 - 08:22
GSK strikes $3.3B Affinivax buyout to MAP out challenge to Pfizer’s blockbuster pneumococcal vaccine
GSK strikes $3.3B Affinivax buyout to MAP out challenge to Pfizer's blockbuster pneumococcal vaccine ntaylor Tue, 05/31/2022 - 05:20